HK1249007A1 - 減少對患有良性前列腺增生患者的手術的需要的方法 - Google Patents

減少對患有良性前列腺增生患者的手術的需要的方法

Info

Publication number
HK1249007A1
HK1249007A1 HK18107591.8A HK18107591A HK1249007A1 HK 1249007 A1 HK1249007 A1 HK 1249007A1 HK 18107591 A HK18107591 A HK 18107591A HK 1249007 A1 HK1249007 A1 HK 1249007A1
Authority
HK
Hong Kong
Prior art keywords
surgery
reducing
methods
need
patients suffering
Prior art date
Application number
HK18107591.8A
Other languages
English (en)
Inventor
Paul Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of HK1249007A1 publication Critical patent/HK1249007A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK18107591.8A 2015-07-24 2018-06-11 減少對患有良性前列腺增生患者的手術的需要的方法 HK1249007A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/808,731 US11628202B2 (en) 2015-07-24 2015-07-24 Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
PCT/US2016/043850 WO2017019593A1 (en) 2015-07-24 2016-07-25 Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
HK1249007A1 true HK1249007A1 (zh) 2018-10-26

Family

ID=56682253

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107591.8A HK1249007A1 (zh) 2015-07-24 2018-06-11 減少對患有良性前列腺增生患者的手術的需要的方法

Country Status (18)

Country Link
US (1) US11628202B2 (zh)
EP (1) EP3324994B1 (zh)
JP (1) JP6884134B2 (zh)
KR (1) KR20180037986A (zh)
CN (1) CN108025037A (zh)
AU (1) AU2016297890B2 (zh)
BR (1) BR112018001533A2 (zh)
CA (1) CA2993548A1 (zh)
DK (1) DK3324994T3 (zh)
ES (1) ES2872730T3 (zh)
HK (1) HK1249007A1 (zh)
HU (1) HUE054137T2 (zh)
LT (1) LT3324994T (zh)
MX (1) MX2018001052A (zh)
PL (1) PL3324994T3 (zh)
PT (1) PT3324994T (zh)
SI (1) SI3324994T1 (zh)
WO (1) WO2017019593A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
WO2023150720A2 (en) * 2022-02-04 2023-08-10 Hofseth Biocare Asa Medicinal uses of oligopeptides in combination with an antiandrogen

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006332C (en) 1988-12-21 2003-04-08 Suzanne De La Monte Method of detecting neurological disease or dysfunction
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
JPH06256387A (ja) 1991-06-14 1994-09-13 Suetsuna Yoko 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤
ES2312913T3 (es) 1993-04-20 2009-03-01 The General Hospital Corporation Expresion genica de la proteina de la cadena neural y deteccion de la enfermedad de alzheimer.
BR9711795A (pt) 1996-03-26 2000-06-06 Razvant T Radulescu Peptìdeos tendo propriedades antiproliferativas
AU749348B2 (en) 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
WO1999019347A1 (en) 1997-10-10 1999-04-22 Astrazeneca Ab Synthetic genes with immunomodulatory effects
WO2000034477A2 (en) 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
JP2002542766A (ja) 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
AU3628600A (en) 1999-03-19 2000-10-09 Human Genome Sciences, Inc. 46 human secreted proteins
JP2002539842A (ja) 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４５個のヒト分泌タンパク質
JP2003535570A (ja) 1999-03-26 2003-12-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
EP1171462A2 (en) 1999-03-26 2002-01-16 Human Genome Sciences, Inc. 49 human secreted proteins
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
JP2001264442A (ja) * 2000-03-22 2001-09-26 Fuji Photo Film Co Ltd 画像記録媒体
WO2002000718A2 (en) 2000-06-26 2002-01-03 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
CA2325666A1 (fr) 2000-12-01 2002-06-01 Institut Pasteur Peptides immunogeniques mutes derives de r9m, polynucleotides les codants et leurs usages therapeutiques
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
KR100632903B1 (ko) 2001-03-08 2006-10-13 니목스 파마슈티칼스 코포레이션 신경 사 단백질을 사용하여 종양 및 세포의 제거 또는파괴를 필요로 하는 다른 증상을 치료하는 방법
BR0209630A (pt) * 2001-05-16 2004-03-30 Nymox Corp Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais
CN1582301A (zh) 2001-05-25 2005-02-16 尼莫克斯股份有限公司 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
MXPA04000561A (es) 2001-07-19 2005-02-17 Nymox Corp Peptidos eficaces en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas.
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7642063B2 (en) 2004-05-19 2010-01-05 Auburn University Methods for targeting and killing glioma cells
US8067378B2 (en) 2006-02-28 2011-11-29 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
JP2009529503A (ja) 2006-03-10 2009-08-20 ナイモックス コーポレーション 神経糸状タンパク質由来ペプチドを用いて癌を予防するまたはその危険度または発生率を減少させる方法
US9243035B2 (en) 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US20160215031A1 (en) 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
JP6256387B2 (ja) 2015-03-09 2018-01-10 株式会社豊田自動織機 電動圧縮機
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Also Published As

Publication number Publication date
HUE054137T2 (hu) 2021-08-30
CA2993548A1 (en) 2017-02-02
SI3324994T1 (sl) 2021-08-31
DK3324994T3 (da) 2021-04-26
MX2018001052A (es) 2018-11-09
KR20180037986A (ko) 2018-04-13
ES2872730T3 (es) 2021-11-02
BR112018001533A2 (pt) 2019-02-12
JP6884134B2 (ja) 2021-06-09
JP2018520200A (ja) 2018-07-26
CN108025037A (zh) 2018-05-11
AU2016297890B2 (en) 2021-08-19
PL3324994T3 (pl) 2021-08-16
US20170020957A1 (en) 2017-01-26
AU2016297890A1 (en) 2018-02-15
LT3324994T (lt) 2021-05-25
EP3324994A1 (en) 2018-05-30
US11628202B2 (en) 2023-04-18
WO2017019593A1 (en) 2017-02-02
EP3324994B1 (en) 2021-04-14
PT3324994T (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HK1249007A1 (zh) 減少對患有良性前列腺增生患者的手術的需要的方法
HK1258205A1 (zh) 用於治療血紅蛋白病的組合物和方法
EP3551100A4 (en) MEDICAL DEVICES FOR TREATING HARD TISSUES AND RELATED PROCESSES
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
ZA201900960B (en) Methods and compositions for the treatment of cancer
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
ZA201808232B (en) Compositions and methods for the treatment of cancer
IL248210A0 (en) Methods and preparations for the treatment of blood vessel malformations
EP3626256C0 (fr) Composition pour le traitement des lésions tissulaires
EP3185910A4 (en) Methods and compositions for the treatment of cancer
GB201506654D0 (en) Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia
ZA201900984B (en) Methods and compositions for the treatment of warts
IL265824A (en) Methods and pharmaceutical compositions for the treatment of kidney cancer
HK1258073A1 (zh) 治療細胞質糖原貯積失調的方法和組合物
HK1255695A1 (zh) 用於治療眼瞼下垂的組合物和方法
IL272147A (en) Methods and preparations for the treatment of cancer
IL256413B (en) IL-8 inhibitors for use in the treatment of certain urological disorders
ZA201706986B (en) Compositions for the treatment of kidney and/or liver disease
GB201621183D0 (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia
EP3365013A4 (en) METHODS AND COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF CANCER
GB201523005D0 (en) The traditional chinese medicine combination for the treatment of bone hyperplasia
PT3128938T (pt) Dispositivo bipolar para a ressecção cirúrgica de tecidos